Pradžia › Mielofibrozė › Ohio
Mielofibrozė klinikiniai tyrimai Ohio
17 tyrimai dėl Mielofibrozė ieško dalyvių vietose Ohio.
Miestai Ohio
Oficialus tyrimo tekstas (anglų kalba)
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
- Ohio State University, Columbus
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-10-02 · NCT04176198A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
- The Ohio State University Comprehensive Cancer Center, Columbus
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-10-02 · NCT07357727A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
- Cleveland Clinic, Cleveland
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-10-01 · NCT07623161A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
- Ohio State University Comprehensive Cancer Center, Columbus
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-30 · NCT06661915Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
- Cleveland Clinic, Cleveland
- The Ohio State University, Columbus
- Taylor Cancer Research Center, Maumee
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-23 · NCT05320198A Phase 1 Study of LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)
- University of Cincinnati, Cincinnati
- The Ohio State University Comprehensive Cancer Center, Columbus
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-17 · NCT06343805Pacritinib Effectiveness in Real-world Settings
- The Ohio State University, Columbus
Renkami dalyviaiStebimasis tyrimas
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-14 · NCT07774455A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis
- Cleveland Clinic, Cleveland
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-07-28 · NCT06773195Study of INCA036978 in Participants With Myeloproliferative Neoplasms
- Cleveland Clinic, Cleveland
- Ohio State University, Columbus
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-07-22 · NCT07441694Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)
- The Cleveland Clinic Foundation, Cleveland
- The Ohio State University, Columbus
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-05-06 · NCT05835466Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
- Cincinnati Children's Hospital Medical Center, Cincinnati
- University of Cincinnati, Cincinnati
- The Ohio State University, Columbus
Renkami dalyviai1 fazė
Amžius 13 ir vyresni · Visoms lytims · Atnaujinta 2026-05-05 · NCT04771572A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
- Cleveland Clinic, Cleveland
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-04-17 · NCT06034002A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 6007), Columbus
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-04-02 · NCT06351631A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
- Cleveland Clinic, Cleveland
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-02-12 · NCT05980806SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Cincinnati
- Massive Bio SYNERGY-AI site, Columbus
- Massive Bio SYNERGY-AI site, Mayfield Heights
Renkami dalyviaiStebimasis tyrimas
Visi amžiai · Visoms lytims · Atnaujinta 2025-10-28 · NCT03452774Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
- Gabrail Cancer Center, Canton
- University of Cincinnati Medical Center, Cincinnati
- Cleveland Clinic Cancer Center at Fairview Hospital, Cleveland
- ir dar 3
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2025-09-25 · NCT06479135Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib
- Gabrail Cancer Center, Canton
- University of Cincinnati (UC), Cincinnati
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2023-02-21 · NCT05280509Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.